nach oben

Erschienen in:

16.10.2023 | Original Article

Mid-term outcomes of surgical aortic valve replacement using a mosaic porcine bioprosthesis with concomitant mitral valve repair

verfasst von: Haruhiko Sugimori, Tatsuya Nakao, Yukikatsu Okada, Yutaka Okita, Hitoshi Yaku, Junjiro Kobayashi, Hideyuki Uesugi, Shuichiro Takanashi, Toshiaki Ito, Tadaaki Koyama, Taichi Sakaguchi, Kouji Yamamoto, Yasushi Yoshikawa, Yoshiki Sawa

Erschienen in: Heart and Vessels | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

This study retrospectively evaluated the mid-term outcomes of surgical aortic valve replacement (SAVR) using a stented porcine aortic valve bioprosthesis (Mosaic; Medtronic Inc., Minneapolis, MN, USA) with concomitant mitral valve (MV) repair. From 1999 to 2014, 157 patients (median [interquartile range] age, 75 [70–79] years; 47% women) underwent SAVR with concomitant MV repair (SAVR + MV repair), and 1045 patients (median [interquartile range] age, 76 [70–80] years; 54% women) underwent SAVR only at 10 centers in Japan as part of the long-term multicenter Japan Mosaic valve (J-MOVE) study. The 5-year overall survival rate was 81.5% ± 4.1% in the SAVR + MV repair group and 85.1% ± 1.4% in the SAVR only group, and the 8-year overall survival rates were 75.2% ± 5.7% and 78.1% ± 2.1%, respectively. Cox proportional hazards analysis showed no significant difference in the survival rates between the two groups (hazard ratio, 0.87; 95% confidence interval, 0.54–1.40; P = 0.576). Among women with mild or moderate mitral regurgitation who were not receiving dialysis, those who underwent SAVR + MV repair, were aged > 75 years, and had a preoperative left ventricular ejection fraction of 30–75% tended to have a lower mortality risk. In conclusion, this subgroup analysis of the J-MOVE cohort showed relevant mid-term outcomes after SAVR + MV repair.

Nur mit Berechtigung zugänglich

Yoshikawa Y, Okada Y, Okita Y, Yaku H, Kobayashi J, Uesugi H, Takanashi S, Ito T, Nakao T, Koyama T, Sakaguchi T, Yamamoto K, Sawa Y (2020) Long-term outcomes of the Mosaic aortic porcine bioprosthesis in Japan—results from the Japan mosaic valve long-term multicenter study. Circ J 84:1261–1270PubMedCrossRef

Ruel M, Kabila V, Price J, Kulik A, Burwash IG, Mesana TG (2006) Natural history and predictors of outcomes in patients with concomitant functional mitral regurgitation at the time of aortic valve replacement. Circulation 114(1 Suppl):I541–I546PubMed

Schubert SA, Yarboro LT, Madala S, Ayunipudi K, Kron IL, Kem JA, Ailawadi G, Stukenborg GJ, Ghanta RK (2016) Natural history of coexistent mitral regurgitation after aortic valve replacement. J Thorac Cardiovasc Surg 151:1032–1042PubMedCrossRef

Nombela-Franco L, Ribeiro HB, Urena M, Allende R, Amat-Santos I, DeLarochelliere R, Dumont E, Doyle D, DeLarochelliere H, Laflamme J, Laflamme L, Garcia E, Macaya C, Jimenez-Quevedo P, Cote M, Bergeron S, Beaudoin J, Pibarot P, Rodes-Cabau J (2014) Significant mitral regurgitation left untreated at the time of aortic valve replacement. J Am Coll Cardiol 63:2643–2658PubMedCrossRef

Fojt R, Motovska Z, Budera P, Maly M, Straka Z (2016) Prognostic impact and change of concomitant mitral regurgitation after surgical or transcatheter aortic valve replacement for aortic stenosis. J Cardiol 67:526–530PubMedCrossRef

Sannino A, Grayburn PA (2018) Mitral regurgitation in patients with severe aortic stenosis: diagnosis and management. Heart 104:16–22PubMedCrossRef

Patel KM, Desai RG, Krishnan S (2021) Mitral regurgitation in patients with coexisting chronic aortic regurgitation: an evidence-based narrative review. J Cardiothorac Vasc Anesth 35:3404–3415PubMedCrossRef

Doldi PM, Steffen J, Stolz L, Fischer J, Stocker TJ, Orban M, Theiss H, Rizas K, Sadoni S, Hagl C, Massberg S, Hausleiter J, Braun D, Deseive S (2023) Impact of mitral regurgitation aetiology on the outcomes of transcatheter aortic valve implantation. EuroIntervention 19(6):526–536PubMedCrossRef

Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP III, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O’Gara PT, Rigolin VH, Sundt TM III, Thompson A, Toly C (2021) 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 143:e72–e227PubMed

10.

Izumi T, Eishi K, Ashihara K, Arita T, Otsuji Y, Kunihara T, Komiya T, Shibata T, Seo Y, Daimon M, Takanashi S, Tanaka H, Nakatani S, Ninami H, Nishi H, Hayashida K, Yaku H, Yamaguchi J, Yamamoto K, Watanabe H, Abe Y, Amaki M, Amano M, Obase K, Tabata M, Miura T, Miyake M, Murata M, Watanabe N, Akasaka T, Okita Y, Kimura T, Sawa Y, Yoshida K, Japanese Circulation Society Joint Working Group (2020) JCS/JATS/JSCS 2020 guideline on the management of valvular heart disease. Circ J 84:2037–2119CrossRef

11.

Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast BD, Sádaba JR, Tribouilloy C, Wojakowski W, ESC/EACTS Scientific Document Group (2022) 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 43:561–632CrossRef

12.

Witberg G, Codner P, Landes U, Schwartzenberg S, Barbanti M, Valvo R, De Becker O, Ooms JF, Islas F, Marroquin L, Sedaghat A, Sugiura A, Masiero G, Werner P, Armario X, Fiorna C, Arzamendi D, Santos-Martines S, Fernandez-Vazquez F, Baz JA, Steblovnik K, Mauri V, Adam M, Merdler I, Hein M, Ruile P, Grasso C, Branca L, Estevez-Loureiro R, Benito-Gonzalez T, Amat-Santos IJ, Mylotte D, Andreas M, Bunc M, Tarantini G, Sinning J-M, Nombela-Franco L, Sondergaard L, Van Mieghem NM, Finkelstein A, Kornowski R (2021) Effect of transcatheter aortic valve replacement on concomitant mitral regurgitation and its impact on mortality. JACC Cardiovasc Interv 14:1181–1192PubMedCrossRef

13.

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377–381PubMedCrossRef

14.

Akins CW, Miller DC, Turina MI, Kouchoukos NT, Blackstone EH, Grunkemeier GL, Takkenberg JJM, David TE, Butchart EG, Adams DH, Shahian DM, Hagl S, Mayer JE, Lytle BW (2008) Guidelines for reporting mortality and morbidity after cardiac valve interventions. Ann Thorac Surg 85:1490–1495PubMedCrossRef

15.

Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, Hahn RT, Han Y, Hung J, Lang RM, Little SH, Shah DJ, Shernan S, Thavendiranathan P, Thomas JD, Weissman NJ (2017) Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 30:303–371PubMedCrossRef

16.

Farewell V, Johnson T (2016) Major Greenwood (1880–1949): a biographical and bibliographical study. Stat Med 35:645–670MathSciNetPubMedCrossRef

17.

Pai RG, Varadarajan P (2010) Prognostic implications of mitral regurgitation in patients with severe aortic regurgitation. Circulation 122(11 Suppl):S43–S47PubMed

18.

McCarthy FH, Desai ND, Fox Z, George J, Moeller P, Vallabhajosyula P, Szeto WY, Bavaria JE (2014) Moderate mitral regurgitation in aortic root replacement surgery: comparing mitral repair with no mitral repair. J Thorac Cardiovasc Surg 147:938–941PubMedCrossRef

19.

Medranda GA, Schwartz R, Green SJ (2020) Predictors and outcomes impact of mitral regurgitation in transcatheter aortic valve replacement. Cardiovasc Revasc Med 32:35–40PubMedCrossRef

20.

Toggweiler S, Boone RH, Rodés-Cabau J, Humphries KH, Lee M, Nombela-Franco L, Bagur R, Willson AB, Binder RK, Gurvitch R, Grewal J, Moss R, Munt B, Thompson CR, Freeman M, Ye J, Cheung A, Dumont E, Wood DA, Webb JG (2012) Transcatheter aortic valve replacement: outcomes of patients with moderate or severe mitral regurgitation. J Am Coll Cardiol 59:2068–2074PubMedCrossRef

21.

Shingu Y, Iwano H, Murakami T, Katoh N, Ooka T, Katoh H, Kubota S, Matsui Y (2019) Risk factors for residual mitral regurgitation after aortic valve replacement in patients with severe aortic valve stenosis and moderate mitral regurgitation. Gen Thorac Cardiovasc Surg 67:849–854PubMedCrossRef

22.

De Bonis M, Lapenna E, Maisano F, Barili F, La Canna G, Buzzatti N, Pappalardo F, Calabrese M, Nisi T, Alfieri O (2014) Long-term results (≤18 years) of the edge-to-edge mitral valve repair without annuloplasty in degenerative mitral regurgitation implications for the percutaneous approach. Circulation 130:S19–S24PubMedCrossRef

23.

Messika-Zeitoun D, Nickenig G, Latib A, Kuck KH, Baldus S, Schueler R, La Canna G, Agricola E, Kreidel F, Huntgeburth M, Zuber M, Verta P, Grayburn P, Vahanian A, Maisano F (2019) Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes. Eur Heart J 40:466–472PubMedCrossRef

24.

Carpentier AF, Lessana A, Relland JYM, Belli E, Mihaileanu S, Berrebi AJ, Palsky E, Loulmet DF (1995) The “Physio-Ring”: an advanced concept in mitral valve annuloplasty. Ann Thorac Surg 60(5):1177–1185PubMedCrossRef

25.

Cosgrove DM III, Arcidi JM, Rodriguez L, Stewart WJ, Powell K, Thomas JD (1995) Initial experience with the Cosgrove-Edwards annuloplasty system. Ann Thorac Surg 60:499–504PubMedCrossRef

26.

Gillinov AM, Cosgrove DM III, Shiota T, Qin J, Tsujino H, Stewart WJ, Thomas JD, Porqueddu M, White JA, Blackatone EH (2000) Cosgrove-Edwards annuloplasty system: midterm results. Ann Thorac Surg 69:717–721PubMedCrossRef

27.

Lange R, Guenther T, Kiefer B, Noebauer C, Goetz W, Busch R, Tassani-Prell P, Voss B, Bauernschmitt R (2008) Mitral valve repair with the new semirigid partial Colvin-Galloway future annuloplasty. J Thorac Cardiovasc Surg 135:1087–1093PubMedCrossRef

28.

Vohra HA, Whistance RN, Bezuska L, Livesey SA (2011) Initial experience of mitral valve repair using the Carpentier-Edwards Physio II annuloplasty ring. Eur J Cardiothorac Surg 39:881–885PubMedCrossRef

29.

Carpentier A, Adams DH, Filsoufi F (2010) Carpentier’s reconstructive valve surgery from valve analysis to reconstruction. Saunders, Philadelphia, pp 69–75 and pp 151–152

30.

Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajil AJ (2001) Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 103:1759–1764PubMedCrossRef

31.

Barreiro CJ, Patel ND, Fitton TP, Williams JA, Bonde PN, Chan V, Alejo DE, Gott VL, Baumgartner WA (2005) Aortic valve replacement and concomitant mitral valve regurgitation in the elderly: impact on survival and functional outcome. Circulation 112:I443–I447PubMedCrossRef

32.

Cortes C, Amat-Santos IJ, Nombela-Franco L, Munos-Garcia AJ, Gutierrez-Ibanes E, De La Torre Hernandez JM, Cordoba-Soriano JG, Jimenez-Quevedo P, Hernandez-Garcia JM, Gonzalez-Mansilla A, Ruano J, Jimenez-Mazuecos J, Gastrodeza J, Tobara J, Islas F, Revilla A, Puri R, Puerto A, Gomez I, Rodes-Cabau J, San Roman JA (2016) Mitral regurgitation after transcatheter aortic valve replacement prognosis, imaging predictors, and potential management. JACC Cardiovasc Interv 9:1603–1614PubMedCrossRef

33.

Mavromatis K, Thourani VH, Stebbins A, Vemullapalli S, Devireddy C, Guyton RA, Matsouka R, Ghasemzadeh N, Block PC, Leshnower BG, Stewart JP, Rumsfeld JS, Lerakis S, Babaliaros V (2017) Transcatheter aortic valve replacement in patients with aortic stenosis and mitral regurgitation. Ann Thorac Surg 104:1977–1986PubMedCrossRef

34.

Gillinov AM, Blackstone EH, Alaulaqi A, Sabik JF 3rd, Mihaljevic T, Svensson LG, Houghtaling PL, Salemi A, Johnston DR, Lytle BW (2008) Outcomes after repair of the anterior mitral leaflet for degenerative disease. Ann Thorac Surg 86:708–717PubMedCrossRef

35.

Okada Y, Nasu M, Koyama T, Shomura Y, Yuzaki M, Murashita T, Fukunaga N, Konishi Y (2012) Outcomes of mitral valve repair for bileaflet prolapse. J Thorac Cardiovasc Surg 143:S21–S23PubMedCrossRef

36.

Lazam S, Vanoverschelde JL, Tribouilloy C, Grigioni F, Suri RM, Avierinos JF, de Meester C, Barbieri A, Rusinaru D, Russo A, Pasquet A, Michelena HI, Huebner M, Maalouf J, Clavel MA, Szymanski C, Enriquez-Sarano M, MIDA (Mitral Regurgitation International Database) Investigators (2017) Twenty-year outcome after mitral repair versus replacement for severe degenerative mitral regurgitation: analysis of a large, prospective, multicenter, international registry. Circulation 135:410–422CrossRef

37.

David TE, David CM, Tsang W, Lafreniere-Roula M, Manlhiot C (2019) Long-term results of mitral valve repair for regurgitation due to leaflet prolapse. J Am Coll Cardiol 74:1044–1053PubMedCrossRef

38.

Miura T, Ariyoshi T, Tanigawa K, Matsukuma S, Yokose S, Sumi M, Hisatomi K, Tsuneto A, Hashizume K, Eishi K (2015) Technical aspect of mitral valve repair in Barlow’s valve with prolapse of both leaflets: triangular resection for excess tissue, sophisticated chordal replacement, and their combination (the restoration technique). Gen Thorac Cardiovasc Surg 63:61–70PubMedCrossRef

39.

McCarthy PM, Herborn J, Kruse J, Liu M, Andrei AC, Thomas JD (2022) A multiparameter algorithm to guide repair of degenerative mitral regurgitation. J Thorac Cardiovasc Surg 164:867-876.e5PubMedCrossRef

40.

Chan KMJ, Punjabi PP, Flather M, Wage R, Symmonds K, Roussin I, Rahman-Haley S, Pennell DJ, Milner PJ, Dreyfus GD, Pepper JR (2012) Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral Evaluation (RIME) trial. Circulation 126:2502–2510PubMedCrossRef

41.

Acker MA, Parides M, Perrault LP, Moskowitz A, Gelijns AC, Voisne P, Smith PK, Hung JW, Blackstone EH, Pushes JD, Argenziano M, Gammie JS, Mack M, Ascheim DD, Bagiella E, Moquete EG, Ferguson TB, Horvath KA, Geller NL, Miller MA, Woo YJ, D’Alessandro DA, Ailawadi G, Dagenais F, Gardner TJ, O’Gara PT, Michler RE (2014) Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med 370:23–32PubMedCrossRef

42.

Goldstein D, Moskowitz AJ, Gelijns AC, Ailawadi G, Parades MK, Perrault LP, Hung JW, Voisine P, Dagenais F, Gillinov AM, Thourani V, Argenziano M, Gammie JS, Mack M, Demers P, Atluri P, Rose EA, O’Sullivan K, Williams DL, Bagiella E, Michler RE, Heisei RD, Miller MA, Geller NL, Taddei-Peters WC, Smith PK, Moquete E, Overbey JR, Kron IL, O’Gara PT, Acker MA (2016) Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N Engl J Med 374:344–353PubMedCrossRef

43.

Petrus AHJ, Dekkers OM, Tops LF, Timmer E, Klautz RJM, Braun J (2019) Impact of recurrent mitral regurgitation after mitral valve repair for functional mitral regurgitation: long-term analysis of competing outcomes. Eur Heart J 40:2206–2214PubMedCrossRef

44.

Messas E, Guerrero JL, Handschumacher MD, Conrad C, Chow CM, Sullivan S, Yoganathan AP, Levine RA (2001) Chordal cutting: a new therapeutic approach for ischemic mitral regurgitation. Circulation 104:1958–1963PubMedCrossRef

45.

Calafiore AM, Refaie R, Iaco AL, Asif M, Al Shurafa HS, Al-Amri H, Romeo A, Di Mauro M (2014) Chordal cutting in ischemic mitral regurgitation: a propensity-matched study. J Thorac Cardiovasc Surg 148:41–46PubMedCrossRef

46.

Matsui Y, Fukuda Y, Naito Y, Sasaki S (2004) Integrated overlapping ventriculoplasty combined with papillary muscle plication for severely dilated heart failure. J Thorac Cardiovasc Surg 127:1221–1223PubMedCrossRef

47.

Harmel E, Pausch J, Gross T, Petersen J, Sinning C, Kubitz J, Reichenspurner H, Girdauskas E (2019) Standardized subannular repair improves outcomes in type IIIb functional mitral regurgitation. Ann Thorac Surg 108:1783–1792PubMedCrossRef

48.

Furukawa K, Yano M, Nakamura E, Matsuyama M, Nishimura M, Kawagoe K, Nakamura K (2018) Comparison of mitral competence after mitral repair with papillary muscle approximation versus papillary muscle relocation for functional mitral regurgitation. Heart Vessels 33:72–79PubMedCrossRef

49.

Pausch J, Girdauskas E, Conradi L, Reichenspurner H (2021) Secondary mitral regurgitation repair techniques and outcomes: subannular repair techniques in secondary mitral regurgitation type IIIb. JTCVS Tech 10:92–97PubMedPubMedCentralCrossRef

50.

Kainuma S, Taniguchi K, Toda K, Funatsu T, Miyagawa S, Kondoh H, Masai T, Otake S, Yoshikawa Y, Nishi H, Sakaguchi T, Ueno T, Kuratani T, Daimon T, Sawa Y (2014) Restrictive mitral annuloplasty with or without surgical ventricular reconstruction in ischemic cardiomyopathy: impacts on neurohormonal activation, reverse left ventricular remodelling and survival. Eur J Heart Fail 16:189–200PubMedCrossRef

51.

Kincaid EH, Riley RD, Hines MH, Hammon JW, Kon ND (2004) Anterior leaflet augmentation for ischemic mitral regurgitation. Ann Thorac Surg 78:564–568PubMedCrossRef

52.

de Varennes B, Chaturvedi R, Sidhu S, Cote AV, Shan WLP, Goyer C, Hatzakorzian R, Buithieu J, Sniderman A (2009) Initial results of posterior leaflet extension for severe type IIIb ischemic mitral regurgitation. Circulation 119:2837–2843PubMedCrossRef

53.

Suri RM, Schaff HV (2015) Posterior leaflet detachment, augmentation, and reconstruction for treatment of functional mitral valve regurgitation. Semin Thorac Cardiovasc Surg 27:91–94PubMedCrossRef

54.

Drake DH, Zimmerman KG, Sidebotham DA (2020) Past, current and future management of secondary mitral valve disease: the importance of anatomic staging. Ann Transl Med 8:968PubMedPubMedCentralCrossRef

55.

Wakasa S, Marsui Y, Isomura T, Takanashi S, Yamaguchi A, Komiya T, Cho Y, Kobayashi J, Yaku H, Kokai K, Arai H, Sawa Y (2014) Risk scores for predicting mortality after surgical ventricular reconstruction for ischemic cardiomyopathy: results of a Japan multicenter study. J Thorac Cardiovasc Surg 147:1868–1874PubMedCrossRef

56.

Wakasa S, Matsui Y, Kobayashi J, Cho Y, Yaku H, Matsumiya G, Isomura T, Takanashi S, Usui A, Sakata R, Komiya T, Sawa Y, Saiki Y, Shimizu H, Yamaguchi A, Hamano K, Arai H (2018) Estimating postoperative left ventricular volume: identification of responders to surgical ventricular reconstruction. J Thorac Cardiovasc Surg 156:2088–2098PubMedCrossRef

57.

Cho Y, Wasaka S, Usui A, Minatoya K, Arai H, Yaku H, Yamaguchi A, Komiya T, Matsumiya G, Hamano K, Saiki Y, Matsui Y (2021) Non-heart transplant surgical approaches with mitral valve operation and surgical ventricular reconstruction for non-ischemic dilated cardiomyopathy: a Japanese multicenter study. Gen Thorac Cardiovasc Surg 69:679–689PubMedCrossRef

58.

Ishigaki T, Wasaka S, Shingu Y, Ohkawa Y, Yamada A, Anzai T, Matsui Y (2022) Reduction of tethering distance by papillary muscle tugging approximation with mitral valve replacement for non-ischemic functional mitral regurgitation induces left ventricular reverse remodeling. J Cardiol 79:530–536PubMedCrossRef

59.

Talwar S, Mathur A, Choudhary SK, Singh R, Kumar AS (2007) Aortic valve replacement with mitral valve repair compared with combined aortic and mitral valve replacement. Ann Thorac Surg 84:1219–1225PubMedCrossRef

60.

Urban M, Pirk J, Turek D, Netuka I (2011) In patients with concomitant aortic and mitral valve disease is aortic valve replacement with mitral valve repair superior to double valve replacement? Interact Cardiovasc Thorac Surg 12:238–242PubMedCrossRef

61.

Thourani VH, Suri RM, Rankin JS, He X, O’Brien SM, Badhwar V, Ailawadi G, Vassileva CM, Shults CC, Svensson LG, Gammie JS (2014) Does mitral valve repair offer an advantage over replacement in patients undergoing aortic valve replacement? Ann Thorac Surg 98:598–603PubMedCrossRef

62.

Kilic A, Grimm JC, Magruder JT, Sciortino CM, Whitman GJR, Baumgartner WA, Conte JV (2015) Trends, clinical outcomes, and cost implications of mitral valve repair versus replacement, concomitant with aortic valve replacement. J Thorac Cardiovasc Surg 149:1614–1619PubMedCrossRef

63.

Riess FC, Cramer E, Hansen L, Schiffelers S, Wahl G, Wallrath J, Winkel S, Kremer P (2010) Clinical results of the Medtronic Mosaic porcine bioprosthesis up to 13 years. Eur J Cardiothorac Surg 37:145–153PubMedCrossRef

64.

Jamieson WRE, Riess FC, Raudkivi PJ, Metras J, Busse EFG, Goldstein J, Fradet GJ (2011) Medtronic Mosaic porcine bioprosthesis: assessment of 12-year performance. J Thorac Cardiovasc Surg 142:302-307.e2PubMedCrossRef

65.

Anselmi A, Flecher E, Ruggieri VG, Harmouche M, Langanay T, Corbineau H, Verhoye JP, Leguerrier A (2014) Long-term results of the Medtronic Mosaic porcine bioprosthesis in the aortic position. J Thorac Cardiovasc Surg 147:1884–1891PubMedCrossRef

66.

Riess FC, Fradet G, Lavoie A, Legget M (2018) Long-term outcomes of the Mosaic bioprosthesis. Ann Thorac Surg 105:763–769PubMedCrossRef

67.

D’Onofrio A, Salizzoni S, Filippini C, Tessari C, Bagozzi L, Messina A, Troise G, Tomba MD, Rambaldini M, Dalén M, Alamanni F, Massetti M, Mignosa C, Russo C, Salvador L, Di Bartolomeo R, Maselli D, De Paulis R, Alfieri O, De Filippo CM, Portoghese M, Bortolotti U, Rinaldi M, Gerosa G (2020) Surgical aortic valve replacement with new-generation bioprostheses: sutureless versus rapid-deployment. J Thorac Cardiovasc Surg 159:432–442PubMedCrossRef

68.

Williams ML, Flynn CD, Mamo AA, Tian DH, Kappert U, Wilbring M, Folliguet T, Fiore A, Miceli A, D’Onofrio A, Cibin G, Gerosa G, Glauber M, Fischlein T, Pollari F (2020) Long-term outcomes of sutureless and rapid-deployment aortic valve replacement: a systematic review and meta-analysis. Ann Cardiothorac Surg 9:265–279PubMedPubMedCentralCrossRef

69.

Stegmeier P, Schlömicher M, Steigler H, Strauch JT, Bechtel JFM (2019) Thrombocytopenia after implantation of the Perceval S aortic bioprosthesis. J Thorac Cardiovasc Surg 160:61–68PubMedCrossRef

70.

Wacker M, Slottosch I, Scherner M, Varghese S, Wippermann J (2019) Late onset valve dislocation of the Edwards Intuity rapid-deployment bioprosthesis. Ann Thorac Surg 107:e243–e244PubMedCrossRef

71.

Okuno T, Tomii D, Heg D, Lanz J, Praz F, Stortecky S, Reineke D, Windecker S, Pilgrim T (2022) Five-year outcomes of mild paravalvular regurgitation after transcatheter aortic valve implantation. EuroIntervention 18(1):33–42PubMedPubMedCentralCrossRef

72.

Vassileva CM, Boley T, Markwell S, Hazelrigg S (2011) Meta-analysis of short-term and long-term survival following repair versus replacement for ischemic mitral regurgitation. Eur J Cardiothorac Surg 39:295–303PubMedCrossRef

73.

Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R (2016) Prosthetic heart valve thrombosis. J Am Coll Cardiol 68:2670–2689PubMedCrossRef

74.

Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ, Investigators COAPT (2018) Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379:2307–2318PubMedCrossRef

75.

Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, Lefèvre T, Piot C, Rouleau F, Carrié D, Nejjari M, Ohlmann P, Leclercq F, Saint Etienne C, Teiger E, Leroux L, Karam N, Michel N, Gilard M, Donal E, Trochu JN, Cormier B, Armoiry X, Boutitie F, Maucort-Boulch D, Barnel C, Samson G, Guerin P, Vahanian A, Mewton N, Investigators MITRA-FR (2018) Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 379:2297–2306PubMedCrossRef

76.

McCarthy PM, Kislitsina ON, Malaisrie SC, Davidson CJ (2019) Transcatheter mitral valve replacement with Intrepid. Interv Cardiol Clin 8:287–294PubMed

77.

Adams DH, Rosenhek R, Falk V (2010) Degenerative mitral valve regurgitation: best practice revolution. Eur Heart J 31:1958–1966PubMedPubMedCentralCrossRef

78.

Burki T (2022) Pig-heart transplantation surgeons look to the next steps. Lancet 399:347PubMedCrossRef

79.

Farr M, Stehlik J (2022) Heart xenotransplant: a door that is finally opening. Circulation 145:871–873PubMedCrossRef

80.

Smood B, Hara H, Cleveland DC, Cooper DKC (2019) In search of the ideal valve: optimizing genetic modifications to prevent bioprosthetic degeneration. Ann Thorac Surg 108:624–635PubMedPubMedCentralCrossRef

Titel: Mid-term outcomes of surgical aortic valve replacement using a mosaic porcine bioprosthesis with concomitant mitral valve repair
verfasst von: Haruhiko Sugimori
Tatsuya Nakao
Yukikatsu Okada
Yutaka Okita
Hitoshi Yaku
Junjiro Kobayashi
Hideyuki Uesugi
Shuichiro Takanashi
Toshiaki Ito
Tadaaki Koyama
Taichi Sakaguchi
Kouji Yamamoto
Yasushi Yoshikawa
Yoshiki Sawa
Publikationsdatum: 16.10.2023
Verlag: Springer Japan
Erschienen in: Heart and Vessels / Ausgabe 3/2024
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-023-02325-x

Neu im Fachgebiet Kardiologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Mid-term outcomes of surgical aortic valve replacement using a mosaic porcine bioprosthesis with concomitant mitral valve repair

Abstract

Neu im Fachgebiet Kardiologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2024

Treatment with catheter ablation for patients with arrhythmia-induced cardiomyopathy caused by atrial fibrillation promises a good prognosis

Soluble ST2, BCN-Bio-HF calculator and MAGGIC-HF score in long-term risk prediction after an urgent visit for heart failure

Impact of the intra-aortic balloon pump on the reliability of the fourth-generation FloTrac/EV1000 system in patients undergoing robotic-assisted off-pump coronary artery bypass surgery

Investigation of the predictive value of a novel algorithm based on coronary CT angiography regarding fractional flow reserve and revascularization in patients with stable coronary artery disease

Prolonged PR intervals are associated with epicardial adipose tissue and recurrence after catheter ablation in persistent atrial fibrillation

Can arterial shape change with IABP play a role in comparing FlowTrac/EV 1000 vs. pulmonary cardiac output?

Neu im Fachgebiet Kardiologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie